[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colon-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colon-surgery":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100641582","the-anorectal-function-and-qol-of-patients-receiving-transrectal-nose-via-rigid-tamis-platform-in-minimal-invasive-colon-surgery-100641582",false,"NCT07653607","The Anorectal Function and QoL of Patients Receiving Transrectal NOSE Via Rigid TAMIS Platform in Minimal Invasive Colon Surgery","A Prospective, Multi-Center, Single-Arm, Open-Label Study to Analyze Anorectal Function and Quality of Life in Patients Undergoing Minimally Invasive Colectomy With Transrectal Natural Orifice Specimen Extraction (NOSE) Using a Rigid Transanal Minimally Invasive Surgery (TAMIS) Platform","Inclusion Criteria:\n\n1. Male or female, aged above 18 years, inclusive.\n2. Patients scheduled for an elective laparoscopic or robotic-assisted colectomy above sigmoid colon.\n3. Deemed a suitable candidate for the Transrectal NOSE procedure by the treating surgical team, based on tumor size (generally, largest diameter \\\u003C 4 cm), tumor T stage(1-3), location, and patient anatomy.\n4. American Society of Anesthesiologists (ASA) physical status classification of I, II, or III.\n5. Able to understand the purpose, procedures, potential risks, and benefits of the study and willing to provide written informed consent, as approved by the Institutional Review Board (IRB).\n6. Willing and able to comply with all scheduled follow-up visits and assessment procedures outlined in the protocol.\n\nExclusion Criteria:\n\n1. Pre-existing moderate-to-severe fecal incontinence, defined as a Wexner incontinence score \\> 8.\n2. History of any prior anal surgery (e.g., sphincteroplasty, artificial sphincter implantation, fistulotomy), major pelvic surgery (e.g., hysterectomy, radical prostatectomy), or pelvic radiation therapy.\n3. Confirmed diagnosis of Inflammatory Bowel Disease (Crohn's disease or ulcerative colitis).\n4. The planned surgical procedure requires a protective stoma.\n5. Uncorrectable coagulopathy identified on preoperative assessment.\n6. Known neurological condition affecting bowel control (e.g., spinal cord injury, multiple sclerosis, significant post-stroke deficits).\n7. Cognitive impairment, severe psychiatric illness, or other condition that would interfere with reliable completion of questionnaires or compliance with the protocol.\n8. Currently pregnant, breastfeeding, or planning to become pregnant during the study period.\n9. Concurrent participation in another interventional clinical trial that could potentially interfere with the study outcomes.\n10. Any other condition which, in the professional opinion of the investigator, makes the subject unsuitable for participation in this study.","ALL","18 Years",{"count":19,"type":20},57,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary objective of this study is to prospectively determine and precisely estimate the incidence of Internal Anal Sphincter (IAS) Injury at 12 months following colectomy with Transrectal NOSE.",[26,27],"Minimal Invasive Surgery","Colon Surgery","NOT_YET_RECRUITING","2026-06-15",{"date":31,"type":32},"2026-06-17","ACTUAL",{"date":34,"type":20},"2026-06-01",{"date":36,"type":20},"2029-07-31",{"name":38,"class":39},"Chang Gung Memorial Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":64,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100566245","sentinel-node-and-organ-sparing-surgery-in-stage-i-colon-carcinoma-100566245","NCT06652672","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma","Sentinel Node and Organ-sparing Surgery in Stage I Colon Carcinoma (SENTRY Trial)","SENTRY","Inclusion Criteria:\n\n* Oral and written informed consent (IC)\n* Aged 18 years and older\n* Fit for both organ-sparing surgery and colectomy\n* Pathologically confirmed T1-2 adenocarcinoma of the colon following R0, R1, or Rx endoscopic resection with an estimated LNM risk \\>15% (Table 5.2.2. in module 5.2 of the Dutch CRC guideline); or a lesion macroscopically suspected to be (deep-invasive) T1 colon cancer, measuring \\\u003C40 mm, for which wedge resection is considered the most suitable local resection technique as recommended by the MDT\n* The resection scar after local excision is expected to be clearly recognized at endoscopy, either by a tattoo or by detecting a scar in the colorectal segment where no other polypectomies were performed\n* Lesion located \\>25cm from the anus based on endoscopic measurement, or above sigmoid take-off\n\nExclusion Criteria:\n\n* Patients who opt for active follow-up instead of surgery following shared decision-making\n* Distant metastasis\n* Lynch syndrome\n* Another active malignancy requiring palliative treatment at the time of colon cancer diagnosis\n* Previous colorectal cancer within the last 5 years\n* Tumours that comprised \\>50% of the colon circumference before resection\n* Tumours involving the ileocaecal valve\n* Pregnancy, lactation or a planned pregnancy during the course of the study\n* Known allergy to any of the compounds used for SLN identification (ICG, Iodine or Sodium iodide)\n* Previous colonic surgery (excluding appendectomy)\n* Contra-indication for laparoscopic or robotic surgery\n* Severe kidney- or liver failure\n* Hyperthyroidism or an autonomously functioning thyroid adenoma",{"count":49,"type":20},341,[23],"The aim of this study is to reduce the need for colectomy and its' associated morbidity and mortality in patients with pT1-2 colon carcinoma after endoscopic resection and an estimated lymph node metastasis (LNM) risk of \\>15%, or with macroscopically suspected T1 tumors, by performing an endoscopic-assisted laparoscopic\u002Frobotic wedge resection of the tumor or scar, along with sentinel node (SLN) biopsy using indocyanine green (ICG). This intervention will be compared to the standard-of-care segmental resection using a partially randomized patient preference design. The primary outcome is the 3-year recurrence rate.",[53,54,55,56,57,58,59,60,61,62,27,63],"Colon Cancer","Colon Adenocarcinoma","Sentinel Lymph Node","Sentinel Lymph Node Biopsy","Colon Neoplasms","Colon Neoplasm","Fluorescence","Fluorescence Guided Surgery","Fluorescence Laparoscopy","Fluorescence-guided Resection","Indocyanine Green (ICG)",[65,59,66,67,68,69,70],"Colon cancer","Sentinel lymph node","Indocyanine green (ICG)","Organ sparing surgery","Organ preserving surgery","Local resection","RECRUITING","2025-11-17",{"date":74,"type":32},"2025-11-20",{"date":76,"type":32},"2024-12-12",{"date":78,"type":20},"2032-12-12",{"name":80,"class":39},"Meander Medical Center",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":21,"phases":92,"briefSummary":94,"conditions":95,"keywords":98,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":112,"leadSponsor":114,"locationsCount":116},"100606827","phase-4-gut-decolonisation-with-neomycinmetronidazole-or-rifaximin-before-colon-surgery-100606827","NCT07180615","Gut Decolonisation With Neomycin\u002FMetronidazole or Rifaximin Before Colon Surgery","Neomycine\u002FMetronidazole- vs Rifaximin-based Gut Decolonisation Prior to Colon Surgery: a Randomized Multicenter Trial","NeoRiDe","Inclusion Criteria:\n\n* aged ≥ 18 years\n* undergoind planned colon surgery\n* colon surgery will be included in Swissnoso SSI surveillance\n* informed consent\n\nExclusion Criteria:\n\n* contraindications and\u002For intolerance to one of the study compounds\n* patients with underlying active infection (wound contamination class IV) at the timepoint of incision\n* pregnant women\n* unable to follow study protocol",{"count":91,"type":20},458,[93],"PHASE4","The goal of this clinical trial is to find out if a gut cleaning using Rifaximin works as well as the usual treatment with Neomycin and Metronidazole to prevent infections after colon surgery. The study includes adult patients who will have colon surgery.\n\nThe main question it aims to answer are:\n\n-Does the Rifaximin treatment prevent surgical site infections as well as the Neomycin\u002FMetronidazole treatment?\n\nOther things the study will look at:\n\n* How often infections happen, stratified on how deep they are, the type of surgery the patients got, or if bowel cleaning was done before surgery.\n* How many people will die after surgery\n* How long people stay in hospital\n\nParticipants will:\n\n* Take either Rifaximin or Neomycin\u002FMetronidazole one day before surgery to clean their gut\n* Keep a diary until the surgery to record medication intake and any side effects\n* Be contacted by phone 30 days after surgery to ask about their condition and any side effects,",[96,27,97],"Surgical Site Infection","Surgical Site Infections",[99,100,101,102,103,104,105,106,107],"SSI","surgical site infection","Metronidazol","flagyl","neomycine","rifaximin","colon surgery","antibiotics","preoperative decolonisation","2025-09-11",{"date":110,"type":32},"2025-09-18",{"date":34,"type":20},{"date":113,"type":20},"2029-06-30",{"name":115,"class":39},"Universität Luzern",4]